Bristol-Myers Squibb (NYSE:BMY - News) and Tibotec Pharmaceuticals, a unit of Johnson & Johnson (NYSE:JNJ - News), will jointly study a potential drug cocktail to treat chronic hepatitis C, an infectious disease that can damage the liver and lead to cirrhosis. The regimen will combine J&J's TMC435 and Bristol-Myers' declatasvir. The study, set to start in early 2012, will include widely used anti-virus drugs interferon and Ribavirin. Fin'l terms weren't disclosed. Bristol-Myers slid 0.4%, J&J fell 1.5%.